title: Biological Therapies of Immunologic Diseases: Strategies for Immunologic Interventions.
abstract: The immune system possesses a vast number of potential targets for therapeutic intervention. Although therapies for many pathways have been pursued, only few have yielded significant success. Hindrances in altering biologic pathways include the potential for unwanted downstream effects, ineffectiveness owing to biological redundancy, recognition of a therapeutic molecule as foreign by the body's innate immune system, and the risks of subsequent malignancy and/or autoimmunity. This article covers currently available biotherapeutic agent classes as well as potential direction for future therapy.
authors.affiliation: Division of Allergy, Asthma and Immunology, Children's Mercy Hospital, 2401 Gillham Road, Kansas City, MO 64108, USA. Electronic address: bpolk@cmh.edu.
authors.forename: Brooke I
authors.initials: BI
authors.lastname: Polk
authors.affiliation: Department of Medicine, University of Missouri Kansas City School of Medicine, 2411 Holmes Street, Kansas City, MO 64108, USA.
authors.forename: Lanny J
authors.initials: LJ
authors.lastname: Rosenwasser
mesh_terms: D000818:Animals; D000911:Antibodies, Monoclonal / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use; D001691:Biological Therapy / Q000379:methods; D016207:Cytokines / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use; D006801:Humans; D007154:Immune System Diseases / Q000276:immunology / Q000378:metabolism / Q000628:therapy*; D007141:Immunoglobulin Fc Fragments; D047428:Protein Kinase Inhibitors / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use; D012313:RNA / Q000627:therapeutic use; D011993:Recombinant Fusion Proteins / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use; D016896:Treatment Outcome
chemical_list: D000911:Antibodies, Monoclonal; D016207:Cytokines; D007141:Immunoglobulin Fc Fragments; D047428:Protein Kinase Inhibitors; D011993:Recombinant Fusion Proteins; D012313:RNA
keywords: Biotherapeutic; Biotherapy; Immunomodulatory; Monoclonal antibody